Metraipolis › archive › dc_9e504fc9be6a

Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC — Europe PMC PMID:42375394

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42375394
DOI
10.1016/j.omton.2026.201247
License (as archived)
solo-consultazione
Archived
2026-11-01T02:18:42.668Z
SHA-256 of the archived text
fe7fa6f23951cb1a27d6b6281e1c1b1bb3bebccc919ea7cc028492dd970abfda
Stable URL of this page
https://metraipolis.com/documento/dc_9e504fc9be6a

How to cite

Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC — Europe PMC PMID:42375394 — Europe PMC (en), https://europepmc.org/article/MED/42375394 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9e504fc9be6a (Metraipolis archive dc_9e504fc9be6a, sha256 fe7fa6f23951cb1a27d6b6281e1c1b1bb3bebccc919ea7cc028492dd970abfda)
BibTeX
@misc{dc9e504fc9be6a,
  title = {Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC — Europe PMC PMID:42375394},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42375394},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9e504fc9be6a; sha256 fe7fa6f23951cb1a27d6b6281e1c1b1bb3bebccc919ea7cc028492dd970abfda},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42375394. Agents can read the archived copy with the MCP tool read_document.